Summary:
Investigators Research Group is conducting a 30 week randomized, double-blinded, placebo-controlled parallel-group, multi-center and multi-national, 4 armed trial. Primary objective to demonstrate superiority of once-weekly dosing of two doses of semaglutide versus placebo on glycaemic control after 30 weeks of treatment in drug-naive subjects with type 2 diabetics.
Qualified Participants Must:
• 18 years of age, or older
•
Have been diagnosed with type 2 Diabetes
•
Not have taken Diabetic medications in the last 90 days
•
Have an HbA1c 7.0-10.0
Qualified Participants May Receive:
Study Medication
, study supplies, study related labs, exams
and compensation for time and travel.